Key Drivers
- Strong Gross Margin
- Cost Overhang
- Liquidity Buffer
AIAI Summary
LEGN should now be viewed as a commercial-stage growth story with real CARVYKTI traction—not a pre-commercial biotech—but the core investment case is still a concentrated, premium-valued bet on one product, so further upside depends on sustained sales execution and eventual pipeline diversification.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Gross Margin
- •Cost Overhang
- •Liquidity Buffer
LEGN generated strong gross profit and solid liquidity in 2025, but heavy operating spending drove full-year and quarterly losses, negative free cash flow, and weak returns despite a premium valuation. ക
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Resistance failure
- •Cooling momentum
LEGN has been in a strong last month uptrend, but the failed push through $28.90-$29.00 and recent pullback to $27.50-$27.60 suggest momentum is cooling and caution is warranted.
Sharp drop to $25.58 before rebounding, showing a brief volatility spike
Sentiment & News
Key News Insights:
- •CARVYKTI Growth
- •Global Expansion
- •Estimate Cuts
Legend Biotech posted strong Q1 momentum as CARVYKTI sales jumped 62% to about $597M with broader global expansion, but cautious analyst revisions temper near-term upside.
The strong sales and expansion outlook support LEGN, but revised estimates and mixed analyst sentiment could cap short-term gains
Similar Companies in Healthcare
Other companies in the same sector with AI ratings